Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Leader in Cancer Research named CEO of ZIOPHARM
Leader in Cancer Research named CEO of ZIOPHARM NEW YORK, NY MAY 1 - Privately-held ZIOPHARM, Inc. announced it named Jonathan J. Lewis, MD, PhD, a founder of the company, to the position of chief executive officer. Dr. Lewis has both academic expertise and industry recognition in product
View HTML
Toggle Summary ZIOPHARM CEO Jonathan J. Lewis Calls For Faster Cancer Drug Development
Drug Candidates Linger Too Long In Irrelevant Animal Studies; Decision To Ditch A Molecule Needs To Come Much Quicker
View HTML
Toggle Summary ZIOPHARM Forms Medical Advisory Board View HTML
Toggle Summary ZIOPHARM Fills Three New Senior Management Posts View HTML
Toggle Summary ZIOPHARM Licenses A New Class Of Arsenic Drugs From M. D. Anderson Cancer Center Smart New Chemistry for Cancer Treatment View HTML
Toggle Summary ZIOPHARM Forms Board of Directors
ZIOPHARM Forms Board of Directors NEW HAVEN, CT SEPT 15 - Privately held ZIOPHARM, Inc., a developer of cancer drugs, announced it named eight individuals with diverse backgrounds in medicine, pharmaceutical and biotechnology management, legal and government affairs, and finance and communications
View HTML
Toggle Summary ZIOPHARM Presents Data on New Class of Arsenic Compounds at International Leukemia Meeting View HTML
Toggle Summary ZIOPHARM Receives ZIO-101 Notice of Patent Allowance Novel Class of Organic Arsenicals Targeted to Enter Clinic in 2005 View HTML
Toggle Summary ZIOPHARM Secures Exclusive License to IPM
Phase I Trial Ongoing
View HTML
Toggle Summary ZIOPHARM and The University of Texas M.D. Anderson Cancer Center Present Data on ZIO-102 at American Society of Hematology Second Organic Arsenic View HTML